AngioDynamics (ANGO) Reports In-Line Q4 EPS, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
AngioDynamics Reports Fiscal Year 2022 Fourth Quarter and Full-Year Financial Results; Issues Fiscal Year 2023 Guidance
July 12, 2022 7:00 AM EDTFiscal Year 2022 Fourth Quarter Highlights
Net sales of $87.0 million increased 13.2% compared to the prior-year quarter Gross margin of 53.4% declined 170 basis points year over year GAAP loss per share of $0.16 and adjusted earnings per share of $0.01 Cash and cash equivalents at May 31, 2022 were $28.8 millionFull-Year 2022 Highlights
Net sales of $316.2 million increased 8.7% year over year Gross margin declined 150 basis points year over year to 52.4% GAAP loss per share of $0.68 and adjusted earnings per... More